Skip to main content
Clinical Trials/NL-OMON52517
NL-OMON52517
Recruiting
Not Applicable

[18F]Fluoride PET-CT imaging for detection and monitoring of bone formation in spondyloarthritis - [18F]Fluoride PET in SpA

Vrije Universiteit Medisch Centrum0 sites48 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
48
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of psoriatic arthritis according to the 2006 Classification
  • Criteria for Psoriatic Arthritis (CASPAR) or ankylosing spondylitis according
  • to the ASAS criteria
  • Patients with clinically active disease as assessed by a physician;
  • o In PsA defined as clinically active disease with at least one clinically
  • active enthesitis site and a clinical indication to start with Secukinumab
  • o In AS defined as a Bath Ankylosing Spondylitis Disease Activity Index
  • (BASDAI) of 4 or higher and a clinical indication to start with Secukinumab.
  • Treatment with disease modifying anti\-rheumatic drugs (DMARDS) and
  • non\-steroidal anti\-inflammatory drugs (NSAID) is permitted, provided that there

Exclusion Criteria

  • Prior treatment with anti\-IL\-17 (for Secukinumab starters)
  • Treatment with any investigational drug within the previous 3 months.
  • Pregnancy or breast\-feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials